Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
3.350
-0.010 (-0.30%)
Oct 7, 2025, 12:45 PM EDT - Market open

Company Description

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines.

It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.

The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care.

It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.

The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada.

Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Psyence Biomedical Ltd.
Psyence Biomedical logo
CountryCanada
Founded1994
IndustryBiotechnology
SectorHealthcare
Employees12
CEONeil Maresky

Contact Details

Address:
121 Richmond Street West, Penthouse Suite, 1300
Toronto, ON M5H2K1
Canada
Phone416 346 7764
Websitepsyencebiomed.com

Stock Details

Ticker SymbolPBM
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001985062
CUSIP Number74449F100
ISIN NumberCA74449F1009
SIC Code2834

Key Executives

NamePosition
Dr. Neil Maresky M.D.Chief Executive Officer and Director
Jody AufrichtigCo-Founder, Executive Chairman and Strategic Business Development Officer
Warwick Ron Corden-LloydChief Financial Officer
Taryn VosGeneral Counsel

Latest SEC Filings

DateTypeTitle
Oct 6, 2025F-1/A[Amend] Registration statement for certain foreign private issuers
Sep 5, 20256-KReport of foreign issuer
Aug 28, 20256-KReport of foreign issuer
Aug 6, 2025F-3Filing
Jul 25, 202520-F/AFiling
Jul 23, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 25, 202520-FAnnual and transition report of foreign private issuers
Jun 25, 20256-KReport of foreign issuer
Jun 11, 20256-KReport of foreign issuer
May 20, 20256-KReport of foreign issuer